Repligen Corporation (NASDAQ:RGEN) reported earnings of $0.16 per share missing Walls Streets expectations.

ME Staff
-
0

Repligen Corporation (NASDAQ:RGEN) reported Q2 2018 earnings this Morning, coming in at $0.16 per share, missing Wall Street’s estimates of $0.18 per Share. Revenue for the quarter came in at $47.73 million beating analyst estimates of $45.84 million

Recent Insider Trading for Repligen Corporation (NASDAQ:RGEN)

  • On 6/6/2018 Thomas F Ryan Jr, Director, sold 1,932 with an average share price of $44.31 per share and the total transaction amounting to $85,606.92.
  • On 5/21/2018 Anthony Hunt, CEO, sold 16,249 with an average share price of $42.53 per share and the total transaction amounting to $691,069.97.
  • On 5/16/2018 Roy T Eddleman, Major Shareholder, sold 118,850 with an average share price of $42.07 per share and the total transaction amounting to $5,000,019.50.
  • On 5/11/2018 Karen A Dawes, Director, sold 20,000 with an average share price of $41.80 per share and the total transaction amounting to $836,000.00.
  • On 5/9/2018 Nicolas Barthelemy, Director, sold 26,500 with an average share price of $40.54 per share and the total transaction amounting to $1,074,310.00.
  • On 5/9/2018 Roy T Eddleman, Major Shareholder, sold 120,000 with an average share price of $40.62 per share and the total transaction amounting to $4,874,400.00.



    About Company
    Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

    Recent Analyst Rating for Repligen Corporation (NASDAQ:RGEN)



      Recent Trading for Repligen Corporation (NASDAQ:RGEN)
      Shares of Repligen Corporation closed the previous trading session at 47.28 −0.77 1.60% with shares trading hands.